Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension
https://doi.org/10.18087/cardio.2022.5.n1977
Abstract
Metabolic syndrome is a disease the World Health Organization has called a new pandemic of the 21st century. Arterial hypertension is one of the criteria for this diagnosis and a determinant of damage to major target organs. The present clinical case demonstrates an experience of treatment of arterial hypertension associated with metabolic syndrome with a valsartan/sacubitril molecular complex.
Supporting agencies: No conflict of interest is reported.
About the Authors
N. G. Lozhkina
Novosibirsk State Medical University; Institute of Cytology and Genetics, Research Institute of Therapy and Preventive Medicine
Russian Federation
Russian Federation
Doctor of Medical Sciences, professor
Novosibirsk, Russia
A. N. Spiridonov
Novosibirsk State Medical University; Institute of Cytology and Genetics, Research Institute of Therapy and Preventive Medicine
Russian Federation
Russian Federation
ordinator
Novosibirsk, Russia
References
1. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sexand gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacological Research. 2017;120:34–42. DOI: 10.1016/j.phrs.2017.03.008
2. Uryasev O.M., Gorbunova D.Yu., Sherbakova O.N., Pyko A.A. Metabolic syndrome as an unsolved problem of medicine and modern society. Vestnik of the Smolensk State Medical Akademy. 2017;16(1):160–4.
3. Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. European Heart Journal. 2017;38(44):3308–17. DOI: 10.1093/eurheartj/ehx525
4. Wehland M, Simonsen U, Buus NH, Krüger M, Grimm D. An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension. Expert Opinion on Pharmacotherapy. 2020;21(10):1133–43. DOI: 10.1080/14656566.2020.1735356
5. Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS et al. Comparison of BNP and NT-proBNP in Patients with Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure. 2020;13(2):e006541. DOI: 10.1161/CIRCHEARTFAILURE.119.006541
6. Lozhkina N.G., Mukaramov I., Stafeeva E.A., Tolmacheva A.A., Parkhomenko O.M. Choice of optimal basic therapy in patients with chronic heart failure after decompensation episode. Medical & pharmaceutical journal ‘Pulse’. 2020;22(7):60–7. DOI: 10.26787/nydha-2686-6838-2020-22-7-60-67
7. Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR et al. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC: Heart Failure. 2019;7(6):457–65. DOI: 10.1016/j.jchf.2019.02.015
8. Hanssen H, Boardman H, Deiseroth A, Moholdt T, Simonenko M, Kränkel N et al. Personalized exercise prescription in the prevention and treatment of arterial hypertension: a Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension. European Journal of Preventive Cardiology. 2022;29(1):205–15. DOI: 10.1093/eurjpc/zwaa141
9. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149–218. DOI: 10.15829/1560-4071-2020-3-3786
Review
For citations:
Lozhkina N.G., Spiridonov A.N. Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension. Kardiologiia. 2022;62(5):72-74. (In Russ.) https://doi.org/10.18087/cardio.2022.5.n1977
Views:
1254
Email this article 
Post a Comment 
